Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aluminum fluoride-labeled indocyanine green analogue
- Development stage
- Unknown
- Lead developer
- The First Medical Center of Chinese PLA General Hospital
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
The aluminum fluoride-labeled indocyanine green (ICG) analogue is a radiopharmaceutical PET/CT imaging agent developed for the quantitative assessment of liver function. It is designed to mimic the pharmacokinetic properties of indocyanine green, a tricarbocyanine dye traditionally used in clinical practice to evaluate hepatic clearance and functional reserve. By labeling an ICG derivative with fluorine-18 using the aluminum fluoride ([18F]AlF) complexation method (typically via a NOTA chelator), this agent allows for high-resolution, quantitative PET imaging of hepatobiliary transport. The tracer is primarily taken up by hepatocytes through organic anion transporting polypeptides (OATPs) and subsequently excreted into the bile, making it a sensitive tool for evaluating regional liver function in patients with liver cirrhosis or other forms of liver dysfunction.
- Other names
- aluminum fluoride labeled ICG analogue[18F]AlF-labeled indocyanine green analogue18F-AlF-labeled ICG analogue
02
Targets
OATP1B1 (Organic anion transporting polypeptide 1B1)SLCO1B3 (Organic anion transporting polypeptide 1B3)
Beyond the preview
Go deeper on aluminum fluoride-labeled indocyanine green analogue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aluminum fluoride-labeled indocyanine green analogue.